Isothiocyanates as specific antagonists of human SXR

异硫氰酸盐作为人类 SXR 的特异性拮抗剂

基本信息

  • 批准号:
    7492326
  • 负责人:
  • 金额:
    $ 27.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2010-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Adverse drug interactions (ADI), are a major public health problem in the US. A major contributor to both ADI and failure of therapeutic efficacy is genetic variability and/or environmentally-induced (incl. diet) changes in hepatic and intestinal drug disposition. Cytochrome P450 3A4 (CYP3A4) is responsible for the hepatic and intestinal metabolism of numerous xenobiotics, including pharmaceutical compounds, some carcinogens, and several important endogenous steroids. Constitutive and inducible expression of CYP3A4 is regulated by a variety of different transcription factors/pathways. Among the most important determinants of CYP3A4 activity is the hormone nuclear receptor, Steroid and Xenobiotic Receptor (SXR; also known as the Pregnane X-receptor, PXR). Numerous drugs and non-drug chemicals induce CYP3A4 activity by acting as SXR ligands, and can cause significant adverse drug-drug interactions and alter therapeutic efficacy. In studies initially investigating the chemopreventive actions of the dietary phytochemical, sulforaphane (SFN; an isothiocyanate found in broccoli), we found that SFN causes remarkable 'down-regulation of CYP3A4 in human hepatocytes. We then verified this effect in human-derived intestinal cells (LS-180), and then demonstrated that SFN acts as an effective antagonist of ligand binding to SXR at low micromolar concentrations. Additional studies demonstrated that this is a species (human)-specific effect, consistent with known differences in SXR ligands between rodents and humans. In this grant we propose to: 1) further elucidate the molecular mechanisms by which SFN blocks SXR function; 2) evaluate structural analogs of SFN to identify more potent and/or specific SXR antagonists; 3) utilize 'humanized' SXR mice and other in vivo approaches to establish an animal model for human response, and 4) conduct a series of human feeding studies to determine if SFN in broccoli sprouts lowers basal expression of human CYP3A4 and/or interferes with rifampicin-mediated induction of CYP3A4, measured by midazolam clearance. If the basic feeding study identifies an effect on CYP3A4, additional feeding studies are proposed to examine other SFN analogs and further characterize the dose and time course of effects. These results may lead to the development of important new therapeutic and dietary approaches that could reduce adverse drug responses. They could also help explain the large inter-individual variability in CYP3A4 that has been noted for decades. Finally, they could help to further elucidate the risks and benefits of sulforaphane, a potential dietary phytochemical that has been proposed as a safe 'nutraceutical' compound to reduce cancer risk.
描述(由申请人提供):药物不良反应(ADI),是美国的一个主要公共卫生问题。ADI和治疗效果失败的一个主要原因是遗传变异和/或环境诱导(包括。饮食)肝脏和肠道药物处置的变化。细胞色素P450 3A4(CYP3A4)负责多种外源物质的肝脏和肠道代谢,包括药物化合物、一些致癌物质和几种重要的内源性类固醇。细胞色素P3A4的组成性和可诱导性表达受多种不同转录因子/途径的调控。细胞色素P3A4活性的最重要决定因素是激素核受体、类固醇和异种生物受体(SXR;也称为孕烷X受体,PXR)。许多药物和非药物化学物质通过作为SXR配体诱导细胞色素P3A4活性,并可引起显著的药物-药物相互作用和改变治疗效果。在初步研究饮食中的植物化学物质萝卜硫素(SFN;一种在西兰花中发现的异硫氰酸酯)的化学预防作用时,我们发现SFN导致人类肝细胞中CYP3A4的显著下调。然后,我们在人来源的肠道细胞(LS-180)中验证了这一效应,并证明了SFN在低微摩尔浓度下可以有效地拮抗SXR的配体结合。其他研究表明,这是一种物种(人类)特有的效应,与啮齿动物和人类之间SXR配体的已知差异一致。在这项拨款中,我们建议:1)进一步阐明SFN阻断SXR功能的分子机制;2)评估SFN的结构类似物,以寻找更有效和/或更特异的SXR拮抗剂;3)利用‘人源化’SXR小鼠和其他体内方法建立人类反应的动物模型;4)进行一系列人类喂养研究,以确定SFN在西兰花芽中是否降低了人CYP3A4的基础表达,和/或干扰利福平介导的细胞色素P3A4的诱导,通过咪达唑仑清除来衡量。如果基础喂养研究确定了对CYP3A4的影响,则建议进行额外的喂养研究,以检查其他SFN类似物,并进一步表征影响的剂量和时间过程。这些结果可能导致重要的新的治疗和饮食方法的发展,可以减少药物的不良反应。它们还可以帮助解释数十年来一直被注意到的CYP3A4基因的巨大个体间差异。最后,他们可以帮助进一步阐明萝卜硫素的风险和好处,这是一种潜在的饮食植物化学物质,已被建议作为一种安全的“营养”化合物来降低癌症风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David L Eaton其他文献

David L Eaton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David L Eaton', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    8650856
  • 财政年份:
    2014
  • 资助金额:
    $ 27.54万
  • 项目类别:
Project 1: In vitro Studies: Correlate the physical and chemical characteristics
项目 1:体外研究:关联物理和化学特性
  • 批准号:
    8066917
  • 财政年份:
    2010
  • 资助金额:
    $ 27.54万
  • 项目类别:
Isothiocyanates as specific antagonists of human SXR
异硫氰酸盐作为人类 SXR 的特异性拮抗剂
  • 批准号:
    7681060
  • 财政年份:
    2007
  • 资助金额:
    $ 27.54万
  • 项目类别:
Isothiocyanates as specific antagonists of human SXR
异硫氰酸盐作为人类 SXR 的特异性拮抗剂
  • 批准号:
    7776699
  • 财政年份:
    2007
  • 资助金额:
    $ 27.54万
  • 项目类别:
Isothiocyanates as specific antagonists of human SXR
异硫氰酸盐作为人类 SXR 的特异性拮抗剂
  • 批准号:
    7316015
  • 财政年份:
    2007
  • 资助金额:
    $ 27.54万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    6880490
  • 财政年份:
    2005
  • 资助金额:
    $ 27.54万
  • 项目类别:
Pilot Project Program
试点项目计划
  • 批准号:
    6880648
  • 财政年份:
    2005
  • 资助金额:
    $ 27.54万
  • 项目类别:
The FHCRC/UW Toxicogenomics Consortium
FHCRC/华盛顿大学毒物基因组学联盟
  • 批准号:
    7407773
  • 财政年份:
    2001
  • 资助金额:
    $ 27.54万
  • 项目类别:
INTEGRATED ENVIRONMENTAL HEALTH MIDDLE SCHOOL PROJECT
综合环境健康中学项目
  • 批准号:
    6210758
  • 财政年份:
    2000
  • 资助金额:
    $ 27.54万
  • 项目类别:
INTEGRATED ENVIRONMENTAL HEALTH MIDDLE SCHOOL PROJECT
综合环境健康中学项目
  • 批准号:
    6656313
  • 财政年份:
    2000
  • 资助金额:
    $ 27.54万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 27.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了